DECISION related activities at EASL Congress 2025
DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop (1) a reliable prognostic test to identify patients that are at risk for a poor outcome following standard therapy but who may benefit from a novel and personalised combinatorial therapy, and (2) a robust response test to predict the success of a novel combinatorial therapy as opposed to more aggressive solutions like a liver transplant.
DECISION Networking Session at Cirrhosis & Complications Track Hub
Friday, 8th May 2025, 10:00 – 10:30
Agenda:
- Brief intro to DECISION project
Pierre-Emmanuel Rautou, DECISION coordinator - Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF
Theresa Wirtz - Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics
Richard Moreau - Discussion + Conclusion
Pierre-Emmanuel Rautou
DECISION posters and presentations
- 10th May, 10:15 to 11:30h – “Abstract Session – Acute (on Chronic) Liver failure”: Patients with acute decompensation of cirrhosis present a unique methylation signature associated with their outcome;
Presenter: Estefanía Huergo Iglesias
Room: Ring-Larsen Room - 10th May, 10:15 to 11:30h – “Abstract Session – Acute (on Chronic) Liver failure”: Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF
Presenter: Theresa Wirtz
Room: Ring-Larsen Room
Special note
Estefanía Huergo Iglesias has been selected best Young Investigator in the “Basic” category. CONGRATULATIONS!
DECISION members at EASL Congress 2025: Talks
Thursday 8 May
| Time | Talk/Session | Speaker | Part of Session | Room |
| 08:30 – 09:45 | EASL/ESGE/Baveno Future of Hepatology: Endohepatology – expanding frontiers or a passing trend? | Virginia Hernández-Gea (EASL) | Endovascular treatment options for portal hypertensive bleeding
(08:30 – 09:45) |
Benhamou Room |
| 09:00 – 09:10 | Real-world experience with long-term albumin in patients with cirrhosis and ascites | Paolo Caraceni and Enrico Pompili (UNIBO, Bologna) | Journal Club
(08:30 – 09:30) |
Eddleston Room |
| 10:00 – 10:30 | Gore & Associates: From Covered TIPS to TIPS using Controlled Expansion | Jonel Trebicka (WWU, Münster) | Ring-Larsen Room | |
| 15:00 – 16:00 | The liver circadian clock in disease pathogenesis and management | Sara Montagnese (UNIPD, Padova) | Arnold Room | |
| 17:00 – 18:15 | Abstract Session – Rare Liver Diseases | Pavel Strnad (UKA, Aachen) | McIntyre Room | |
| 17:40 – 17:50 | Cirrhosis and complications | Virginia Hernández-Gea (EASL) | The JHEP Reports Symposium: Keys to get your manuscript accepted
(17:00 – 18:00) |
Eddleston Room |
Friday 9 May
| Time | Talk/Session | Speaker | Part of Session | Room |
| 08:30 – 09:45 | Abstract Session – Cirrhosis I | Pierre-Emmanuel Rautou (APHP, Paris) | Benhamou Room | |
| 17:00 – 18:15 | Abstract Session – Fibrosis, Hepatocyte and Liver regeneration | Sophie Lotersztajn (INSERM) | McIntyre Room | |
| 17:35 – 17:50 | Table 3: Building and maintaining a high-performing team | Pierre-Emmanuel Rautou (APHP, Paris) | YI workshop: How to Start a Research Group: From Postdoc to PI
(17:00 – 18:00) |
Eddleston Room |
Saturday 10 May
| Time | Talk/Session | Speaker | Part of Session | Room |
| 08:40 – 08:50 | Is the etiological work-up of PSVD a one-size-fits-all? | Lucile Moga (APHP, Paris) | EASL/VALDIG Do’s and don’ts in the management of Porto-Sinusoidal Vascular Disease
(08:30 – 09:45) |
Hepatology Arena |
| 08:53 – 09:08 | Management of MDR infections in cirrhosis: the hepatologist perspective | Javier Fernández (IDIBAPS, Barcelona) | EASL/ESCMID Symposium: MDR infections – a challenge in decompensated cirrhosis
(08:30 – 09:45) |
Benhamou Room |
DECISION members at EASL: posters
Wednesday, 7th May 2025, 08:30 – 17:00, Poster Area
Poster session: Rare liver diseases (including paediatric and genetic) – Basic
- Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease: long-term efficacy and safety results from a phase 2 extension study; POSTER ID WED-323 (UKA, Aachen)
Presenter: Pavel Strnad (UKA, Aachen)
- 10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis; POSTER ID WED-340
Presenter: Kohilan Gananandan (UCL, London)
Poster session: Non-invasive assesment of liver disease except MASLD
- Validation of Baveno VII criteria for non-invasive diagnosis of clinically significant portal hypertension: systematic review and individual patient data meta-analysis; POSTER ID WED-512-YI
Presenter: Juan Bañares (Vall d’Hebron, Barcelona)
- Bile acids drive fibroblast activation, fibrogenesis, interstitial matrix fibrosis and outcomes in PSC; POSTER ID WED-516
Presenter: Morten Karsdal (NordicBio)
- Weight dependent, weight independent and non-pharmacological effects on fibroblast activity in metabolic dysfunction associated steatotic liver disease (MASLD); POSTER ID WED-517
Presenter: Morten Karsdal (NordicBio)
Poster session: MASLD: Diagnostics and non-invasive assessment
- Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602K during a phase IIb clinical trial; POSTER ID WED-376
Presenter: Alejandro Mayorca Guiliani (NordicBio) - Fibroblast activity (PRO-C3) and liver stiffness correlate with spatial distribution of collagens in MASLD and ALD: insights from digital pathology; POSTER ID WED-404
Presenter: Diana Julie Leeming (NordicBio)
- Poster: PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness; POSTER ID WED-405
Presenter: Diana Julie Leeming (NordicBio)
Poster session: Cirrhosis and its complications: Portal Hypertension
- Treatment response to terlipressin in patients with acute kidney injury – hepatorenal syndrome and preexisting chronic kidney disease – the german liver cirrhosis / CKD-Terli study group; POSTER ID WED-194-YI
Presenter: Frank Erhard Uschner (WWU, Münster)
Thursday, 8th May 2025, 08:30 – 17:00, Poster Area
Poster session: Cirrhosis and its complications: Experimental and pathophysiology
- Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre european cohorts; POSTER ID THU-159-YI
Presenter: Kohilan Gananandan (UCL, London)
Poster session: Fibrosis / Stellate cell biology
- Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease; POSTER ID THU-058-YI
Presenter: Maximilian Joseph Brol (WWU, Münster)
Friday, 9th May 2025, 08:30 – 17:00, Poster Area
Poster session: Cirrhosis and its complications: ACLF and Critical illness
- Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-on-chronic liver failure; POSTER ID FRI-199
Presenter: Maike Rebecca Pollmanns (UKA, Aachen)
- One-week criteria of potential care inappropriateness for patients with acute-on-chronic liver failure not eligible for liver transplantation; POSTER ID FRI-222
Presenter: Thierry Gustot (EF-CLIF, Barcelona)
Poster session: Liver transplantation and hepatobiliary surgery – Clinical
- Poster: Conversion from standard-release to prolonged-release tacrolimus mitigates calcineurin-induced nephrotoxicity in patients after liver transplantation; POSTER ID FRI-493
Presenter: Maximilian Joseph Brol (WWU, Münster)
- Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation; POSTER ID FRI-495-YI
Presenter: Maike Rebecca Pollmanns (UKA, Aachen)
Saturday, 10th May 2025, 08:30 – 17:00, Poster Area
Poster session: Cirrhosis and its complications: Other clinical complications except ACLF and critical illness
- Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes; POSTER ID SAT-122-YI
Presenter: Alberto Calleri (UNITO, Torino)
- Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience; POSTER ID SAT-145-YI
Presenter: Enrico Pompili (UNIBO, Bologna)
- Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis; POSTER ID SAT-184-YI
Presenter: Mimma Bonomo (UNITO, Torino)
Poster session: Alcohol-related liver disease and MetALD – Clinical
- Cardiac performance is impaired in patients with proven alcohol related hepatitis and and predicts 3-month mortality in this patient population; POSTER ID SAT-503-YI
Presenter: Shantha Valainathan (APHP, Paris)
Poster session: Liver transplantation and hepatobiliary surgery – Basic
- The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course; POSTER ID SAT-518
Presenter: Maike Rebecca Pollmanns (UKA, Aachen)